Viatris Inc. Insider Trading

VTRS

Last 12 months

Insiders sold $1.09M and bought nothing on the open market.

74% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Nov 2025.

Net open-market

−$1.09M

0 buys · 2 sales

Under a 10b5-1 plan

74%

of the value sold

Insiders who bought / sold

0 / 1

executives and directors

Last open-market buy

Nov 2025

Nov 3, 2025

Get an email when VTRS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 25	Paul Campbell See Remarks	Sold10b5-1 plan	50,076	$16.17	810K	14%	Form 4
Mar 23	Paul Campbell See Remarks	SoldNo plan	21,350	$13.28	284K	5.5%	Form 4
Aug 27, 2025 – Nov 3, 2025	David S Simmons Director	Bought 2 parts	499	$10.42 average	5K	2.1%	Form 4
Sep 11, 2025	Corinne Le Goff Chief Commercial Officer	Sold10b5-1 plan	7,032	$10.25	72K	17%	Form 4
Aug 12, 2025	Scott Andrew Smith Chief Executive Officer	Bought	22,000	$9.99	220K	7.5%	Form 4
May 12, 2025	Scott Andrew Smith Chief Executive Officer	Bought	60,000	$8.94	536K	26%	Form 4
Nov 11, 2024	Paul Campbell See Remarks	SoldNo plan	26,925	$12.88	347K	17%	Form 4

Jun 2510b5-1 plan
Paul Campbell
See Remarks · sold 50,076 at $16.17
810K
14% of stake
Mar 23No plan
Paul Campbell
See Remarks · sold 21,350 at $13.28
284K
5.5% of stake
Aug 27, 2025 – Nov 3, 2025
David S Simmons
Director · bought 499 at avg $10.42
5K
2.1% of stake
Sep 11, 202510b5-1 plan
Corinne Le Goff
Chief Commercial Officer · sold 7,032 at $10.25
72K
17% of stake
Aug 12, 2025
Scott Andrew Smith
Chief Executive Officer · bought 22,000 at $9.99
220K
7.5% of stake
May 12, 2025
Scott Andrew Smith
Chief Executive Officer · bought 60,000 at $8.94
536K
26% of stake
Nov 11, 2024No plan
Paul Campbell
See Remarks · sold 26,925 at $12.88
347K
17% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch VTRS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with VTRS

CompareIntrinsic value

REGNRegeneron Pharmaceuticals, Inc.

$930.67-4.39%54

VRTXVertex Pharmaceuticals Incorporated

$549.04+3.44%47

TEVATeva Pharmaceutical Industries Ltd

$42.13+0.52%46

UPCUniverse Pharmaceuticals Inc.

$1.47-1.34%39

BHCBausch Health Companies Inc.

$8.34+2.46%56

ZTSZoetis Inc.

$89.21+7.49%79

ONCBeOne Medicines Ltd.

$377.78+6.42%65

OGNOrganon & Co.

$13.83-0.14%28

Held by ETFs

VTRS is in 238 US ETFs. The largest of them, with VTRS's weight in each:

Spot a number that looks wrong? Check it in VTRS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing VTRS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.